Document is current
Any future updates will be listed below
-
Authors
Razak, Khaleel A.
Dominick, Kelli C.
Erickson, Craig A.
-
Funding
Funding for this research was provided by:
National Institutes of Health (U54 HD082008)
- License Information
-
More Information
Article History
Received: 8 May 2019
Accepted: 13 February 2020
First Online: 2 May 2020
Ethics approval and consent to participate
: Not applicable.
: All authors have reviewed the manuscript in detail and consent for publication.
: KAR has no conflicts to report. KCD has received research support from the National Institute of Neurological Disorders and Stroke (NINDS), American Academy of Child and Adolescent Psychiatry, and Cincinnati Children’s Hospital Medical Center. She is a clinical trial site investigator for F. Hoffman-La Roche Ltd. and Ovid Therapeutics. CAE has received current or past funding from Confluence Pharmaceuticals, Novartis, F. Hoffmann-La Roche Ltd., Seaside Therapeutics, Riovant Sciences, Inc., Fulcrum Therapeutics, Neuren Pharmaceuticals Ltd., Alcobra Pharmaceuticals, Neurotrope, Zynerba Pharmaceuticals, Inc., Lenire Bioscience, and Ovid Therapeutics Inc. to consult on trial design or development strategies and/or conduct clinical trials in FXS or other neurodevelopmental disorders. CAE is additionally the inventor or co-inventor on several patents held by the Cincinnati Children’s Hospital Medical Center or Indiana University School of Medicine describing methods of treatment in FXS or other neurodevelopmental disorders.
